Osteogenesis Imperfecta
- 1 November 2000
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 2 (6) , 465-488
Abstract
Osteogenesis imperfecta (OI), an inherited connective tissue disorder of remarkable clinical variability, is caused by a quantitative or qualitative defect in collagen synthesis and is characterised by bone fragility. The number of fractures and deformities, and the age at which they begin greatly influence the prognosis and the achievement of walking and autonomy. A multidisciplinary team approach is essential for diagnosis, for communication with patient and parents, and to tailor treatment needs to the severity of the disease and the age of the patient. Three types of treatment are available: nonsurgical management (physical therapy, rehabilitation, bracing and splinting), surgery (intramedullary rod positioning, spinal and basilar impression surgery), and drugs to increase the strength of bone and decrease the number of fractures. An aggressive rehabilitative approach is indicated to optimise functional ability and walking capacity; appropriately timed surgery to insert intramedullary rods provides improved function of extremities. Despite a high rate of complications, intramedullary telescopic roding has proven to be the most successful method for preventing and correcting fractures and deformities of long bones, improving walking capability and leading to successful rehabilitation of even severely affected patients. Surgery may be required in patients with progressive spinal deformity and in those with symptomatic basilar impression. Hearing function, dentinogenesis imperfecta, cardiac and respiratory function, and neurological changes must be monitored. The causal defect of the disease cannot be corrected with medical treatment and, currently, only symptomatic therapy is available. In recent years growth hormone (GH) and bisphosphonate agents have been used in OI therapy. GH is beneficial in patients with moderate forms of OI, showing a positive effect on bone turnover, bone mineral density and height velocity rate. Bisphosphonates have proved beneficial in children with severe OI, increasing bone mineral density and reducing the fracture rate and pain with no adverse effects reported. These data require confirmation in double-blind controlled studies; however, bisphosphonates have markedly improved morbidity in patients with OI. Future developments in genetic therapy may be directed towards either replacing cells carrying the mutant gene with normal cells or silencing the mutant allele using antisense suppression therapy, thus transforming a biochemically severe form of OI into a mild form.Keywords
This publication has 103 references indexed in Scilit:
- Cyclic Administration of Pamidronate in Children with Severe Osteogenesis ImperfectaNew England Journal of Medicine, 1998
- Osteogenesis imperfecta: Are fractures and growth hormone treatment linked?The Journal of Pediatrics, 1998
- Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesisThe Journal of Pediatrics, 1996
- Intrafamilial variable expressivity of osteogenesis imperfecta due to mosaicism for a lethal G382R substitution in theCOL1A1geneMolecular and Cellular Probes, 1996
- Studies of collagen synthesis and structure in the differentiation of child abuse from osteogenesis imperfectaThe Journal of Pediatrics, 1996
- Adverse Effects of BisphosphonatesDrug Safety, 1996
- Osteogenesis imperfecta, non-accidental injury, and temporary brittle bone disease.Archives of Disease in Childhood, 1995
- Serum concentrations of procollagen I C‐terminal propeptide, osteocalcin and insulin‐like growth factor‐I in patients with non‐lethal osteogenesis irnperfectaActa Paediatrica, 1993
- Osteocalcin levels in osteogenesis imperfectaThe Journal of Pediatrics, 1987
- Plasma osteocalcin levels in patients with osteogenesis imperfectaThe Journal of Pediatrics, 1986